Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Skin and Connective Tissue Diseases

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44349   clinical trials with a EudraCT protocol, of which   7376   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    1,106 result(s) found for: Skin and Connective Tissue Diseases. Displaying page 14 of 56.
    «« First « Previous 10  11  12  13  14  15  16  17  18  Next» Last»»
    EudraCT Number: 2017-002612-14 Sponsor Protocol Number: TMP-0517 Start Date*: 2019-06-25
    Sponsor Name:Fraunhofer Gesellschaft for its Institute Fraunhofer Institute for Molecular Biology and Applied Ecology (IME)
    Full Title: Preliminary efficacy and safety of Apremilast in the treatment of acne conglobata: A phase II, single centre, open label, proof of concept study for the treatment of acne conglobata with the PDE-4 ...
    Medical condition: Mild to severe Acne conglobata in adults (ages 18 to 65 years, inclusive)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10040785 - Skin and subcutaneous tissue disorders 10000501 Acne conglobata PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2020-000720-19 Sponsor Protocol Number: IDI01/2020 Start Date*: 2020-07-22
    Sponsor Name:IDI FARMACEUTICI SRL
    Full Title: A prospective, randomized, multicenter, open- label, two-arm and parallel-group Study to evaluate the efficacy and safety of Nicotinamide DS compared to Ciclopirox olamine cream at 1% in patients a...
    Medical condition: Patients affected by seborrheic dermatitis.
    Disease: Version SOC Term Classification Code Term Level
    21.1 10040785 - Skin and subcutaneous tissue disorders 10039793 Seborrhoeic dermatitis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-000605-72 Sponsor Protocol Number: CB+MSCforEB Start Date*: 2014-02-06
    Sponsor Name:Universitair Medisch Centrum Utrecht
    Full Title: Unrelated cord blood transplantation after reduced toxicity conditioning with mesenchymal stromal cell co-infusion in patients with severe epidermolysis bullosa
    Medical condition: The source population consists of patients referred to or within the UMC Groningen because they have diagnosed clinically and genetically severe generalized RDEB.
    Disease:
    Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: NL (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2020-002366-13 Sponsor Protocol Number: IB2020-02 Start Date*: 2021-12-20
    Sponsor Name:Institut Bergonié
    Full Title: Combination of pembrolizumab and cabozantinib in patients with advanced sarcomas
    Medical condition: Advanced /metastatic sarcomas: undifferentiated pleomorphic sarcoma, osteosarcoma and Ewing sarcoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10039494 Sarcoma NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2017-000066-29 Sponsor Protocol Number: RD.03.SPR.114384 Start Date*: 2017-05-15
    Sponsor Name:Galderma R&D
    Full Title: Subject reported outcomes on satisfaction, efficacy and safety with Luxerm® in the field-directed treatment of thin or non-hyperkeratotic and non-pigmented Actinic Keratosis of the face or the scalp
    Medical condition: Thin or non-hyperkeratotic and non-pigmented Actinic Keratosis on the face and scalp
    Disease: Version SOC Term Classification Code Term Level
    19.1 100000004858 10020648 Hyperkeratoses HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2016-003013-96 Sponsor Protocol Number: AVXCLIN003 Start Date*: 2016-10-03
    Sponsor Name:Avexxin AS
    Full Title: A Randomised, Blinded, Placebo-controlled, Single Centre Pilot Study to evaluate the Safety and Efficacy of AVX001 3% Ointment (NG) administered Topically Once Daily to Patients with mild, moderate...
    Medical condition:
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004858 10003639 Atopic dermatitis LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-019598-13 Sponsor Protocol Number: MOLT-2009-01 Start Date*: 2010-07-27
    Sponsor Name:MOLTENI
    Full Title: A randomised, double-blind, dose-response, placebo-controlled, multicenter, phase IIA clinical study to evaluate the efficacy and safety of topical application of G.68.y/EtOH in patients with type ...
    Medical condition: patients with type 1 or type 2 diabetes with infected foot ulcers
    Disease: Version SOC Term Classification Code Term Level
    14.1 10021881 - Infections and infestations 10021784 Infected skin ulcer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2021-001085-37 Sponsor Protocol Number: IB2021-05 Start Date*: 2021-10-14
    Sponsor Name:Institut Bergonié
    Full Title: Randomized phase II study of neoadjuvant chemotherapy plus retifanlimab (INCMGA00012) plus in patients with selected retroperitoneal sarcomas.
    Medical condition: retroperitoneal sarcomas
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10039494 Sarcoma NOS LLT
    20.0 100000004864 10077289 Retroperitoneal sarcoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2014-005424-97 Sponsor Protocol Number: CIGE025EFR02 Start Date*: 2015-01-28
    Sponsor Name:NOVARTIS PHARMA SAS
    Full Title: A phase IV, multicenter, single-arm and open-label study to explore the impact on quality of life of omalizumab (Xolair®) in patients with chronic spontaneous urticaria (CSU) who remain symptomatic...
    Medical condition: chronic spontaneous urticaria
    Disease: Version SOC Term Classification Code Term Level
    18.0 10040785 - Skin and subcutaneous tissue disorders 10072757 Chronic spontaneous urticaria PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2010-022912-37 Sponsor Protocol Number: MP‐1501‐01 Start Date*: 2012-03-07
    Sponsor Name:Medicis Pharmaceutical Corporation [...]
    1. Medicis Pharmaceutical Corporation
    2. Dow Pharmaceutical Sciences
    Full Title: Multi-centre, open-label, long-term safety trial to assess the long-term safety of tretinoin clindamycin phosphate gel in patients from 12 to less than 18 years of age with acne vulgaris.
    Medical condition: Treatment of Acne vulgaris
    Disease: Version SOC Term Classification Code Term Level
    14.1 10040785 - Skin and subcutaneous tissue disorders 10000497 Acnes HLT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2010-024196-83 Sponsor Protocol Number: CF101-202PS Start Date*: 2011-03-29
    Sponsor Name:Can-Fite BioPharma, Ltd.
    Full Title: A Phase 2/3 Randomized, Double-Blind, Placebo-Controlled, Dose-Finding Study of the Efficacy and Safety of Daily CF101 Administered Orally in Patients with Moderate-to-Severe Plaque Psoriasis
    Medical condition: Moderate-to-Severe Plaque Psoriasis
    Disease: Version SOC Term Classification Code Term Level
    17.1 10040785 - Skin and subcutaneous tissue disorders 10037153 Psoriasis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BG (Completed)
    Trial results: View results
    EudraCT Number: 2011-001889-17 Sponsor Protocol Number: MW2012-01-02 Start Date*: 2011-07-26
    Sponsor Name:MediWound, Ltd.
    Full Title: Scar Formation and Quality of Life assessment in subjects (adults & children) following treatment with Debrase compared to Standard of Care (SOC)
    Medical condition: long term scar formation
    Disease: Version SOC Term Classification Code Term Level
    13.1 10040785 - Skin and subcutaneous tissue disorders 10057061 Burn scar LLT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-022918-15 Sponsor Protocol Number: 7001‐G2HP‐07‐02 Start Date*: 2012-03-07
    Sponsor Name:Dow Pharmaceutical Sciences
    Full Title: Multi-centre, randomized, double-blind, active- and vehicle-controlled trial to compare the efficacy and safety of tretinoin clindamycin phosphate gel to clindamycin phosphate gel alone, tretinoin ...
    Medical condition: Treatment of acne vulgaris
    Disease: Version SOC Term Classification Code Term Level
    14.1 10040785 - Skin and subcutaneous tissue disorders 10000497 Acnes HLT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2010-022919-20 Sponsor Protocol Number: MP-1501-02 Start Date*: 2012-03-07
    Sponsor Name:Dow Pharmaceutical Sciences [...]
    1. Dow Pharmaceutical Sciences
    2. Medicis Pharmaceutical Corporation
    Full Title: Multi-centre, randomized, double-blind trial to compare the efficacy and safety of tretinoin clindamycin phosphate gel to clindamycin phosphate gel alone in the treatment of acne vulgaris in patien...
    Medical condition: Treatment of Acne vulgaris
    Disease: Version SOC Term Classification Code Term Level
    14.1 10040785 - Skin and subcutaneous tissue disorders 10000497 Acnes HLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2011-002058-30 Sponsor Protocol Number: RD.03.SPR.40162E Start Date*: 2011-11-24
    Sponsor Name:Galderma R&D SNC
    Full Title: Effect of CD08100/02 3% gel versus placebo gel in subjects presenting with papulopustular rosacea over a 6-week treatment period.
    Medical condition: Papulopustular rosacea
    Disease: Version SOC Term Classification Code Term Level
    14.0 10040785 - Skin and subcutaneous tissue disorders 10039218 Rosacea PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2010-022911-20 Sponsor Protocol Number: 7001‐G2HP‐06‐02 Start Date*: 2012-03-07
    Sponsor Name:Dow Pharmaceutical Sciences
    Full Title: A Multi-Center, Phase 3, Randomized, Double-Blind, 4-Arm Clinical Trial to Compare the Safety and Efficacy of Clin-RA Gel vs. Clindamycin Phosphate 1.2% Gel vs. Tretinoin 0.025% Gel vs. Clin-RA Gel...
    Medical condition: Treatment of acne vulgaris
    Disease: Version SOC Term Classification Code Term Level
    14.1 10040785 - Skin and subcutaneous tissue disorders 10000497 Acnes HLT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2005-004465-41 Sponsor Protocol Number: P04612 Start Date*: 2006-01-27
    Sponsor Name:SCHERING-PLOUGH
    Full Title: A multi-center, open-label trial evaluating the Efficacy, Safety and the Impact on Quality of Life of Infliximab Therapy in patients with moderate to severe psoriasis not responding and/or intolera...
    Medical condition: Moderate to severe psoriasis.
    Disease: Version SOC Term Classification Code Term Level
    14.1 10040785 - Skin and subcutaneous tissue disorders 10037153 Psoriasis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2012-001044-22 Sponsor Protocol Number: RD.03.SPR.40174 Start Date*: 2012-08-15
    Sponsor Name:Galderma R&D SNC
    Full Title: A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, VEHICLE-CONTROLLED, PARALLEL GROUP STUDY TO DEMONSTRATE THE EFFICACY AND ASSESS THE SAFETY OF CD07805/47 GEL 0.5% APPLIED TOPICALLY ONCE DAILY IN SUBJECTS W...
    Medical condition: Rosacea
    Disease: Version SOC Term Classification Code Term Level
    14.1 10040785 - Skin and subcutaneous tissue disorders 10039218 Rosacea PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: View results
    EudraCT Number: 2011-003746-41 Sponsor Protocol Number: CIGE025EDE14T Start Date*: 2012-01-12
    Sponsor Name:Allergie-Centrum-Charité, Department of Dermatology and Allergy, Charité - Universitätsmedizin Berlin
    Full Title: A two-center, double blind, placebo-controlled study in parallel design to assess the efficacy and safety of 150 and 300 mg omalizumab in subjects with antihistamine-resistant cold contact urticari...
    Medical condition: Cold contact urticaria
    Disease: Version SOC Term Classification Code Term Level
    15.1 10040785 - Skin and subcutaneous tissue disorders 10009869 Cold urticaria PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2009-013037-19 Sponsor Protocol Number: VB-201-006-A Start Date*: 2010-02-08
    Sponsor Name:Vascular Biogenics Ltd.
    Full Title: A Randomized, Double-Blind, 12-Week, Dose-Ranging Placebo-Controlled Study to Evaluate the Efficacy and Safety of Oral VB-201 in Patients with Moderate to Severe Plaque Psoriasis
    Medical condition: Moderate to Severe Plaque Psoriasis
    Disease: Version SOC Term Classification Code Term Level
    14.0 10040785 - Skin and subcutaneous tissue disorders 10050576 Psoriasis vulgaris LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 10  11  12  13  14  15  16  17  18  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed Jul 16 09:49:53 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA